Future Journal of Pharmaceutical Sciences最新文献

{"title":"Transdermal flibanserin cubosomal hydrogel for hypoactive sexual desire disorder: box–behnken optimization and pharmacokinetic profiling in a rat model","authors":"Shaimaa M. Badr-Eldin,&nbsp;Hibah M. Aldawsari,&nbsp;Eman Abdelahkeem,&nbsp;Walaa Abualsunun,&nbsp;Bayan A. Eshmawi,&nbsp;Osama A. A. Ahmed,&nbsp;Sabna Kotta,&nbsp;Marianne J. Naguib","doi":"10.1186/s43094-026-01018-2","DOIUrl":"10.1186/s43094-026-01018-2","url":null,"abstract":"<div><h3>Background</h3><p>Flibanserin is the first non-hormonal pharmacotherapy approved for hypoactive sexual desire disorder but shows limited oral bioavailability of about 33% due to extensive first-pass hepatic metabolism. This limitation reduces systemic exposure and may compromise clinical effectiveness. This study aimed to develop a nanostructured cubosomal hydrogel as a noninvasive transdermal delivery system for flibanserin to bypass first-pass metabolism, sustain drug release, and improve systemic bioavailability. Results: Flibanserin-loaded cubosomes were optimized using a Box–Behnken experimental design by varying the concentrations of monoolein, poloxamer 407, and polyvinyl alcohol to control particle size, entrapment efficiency, and nanostructural properties. The optimized dispersion, containing 9.93% monoolein, 1.36% poloxamer 407, and 0.03% polyvinyl alcohol, exhibited a mean particle size of 234.3 ± 8.6 nm and entrapment efficiency of 83.2 ± 5.7%, with a confirmed bicontinuous cubic structure. Incorporation into a 2% hydroxypropyl methylcellulose K4M hydrogel produced a cubosomal hydrogel with suitable topical characteristics, including a viscosity of 2.15 ± 0.19 Pa.s and spreadability of 4.7 cm. In rats, transdermal administration of the flibanserin cubosomal hydrogel achieved superior systemic exposure compared with an oral suspension, with 1.97-fold increase in relative bioavailability based on AUC_0−∞ from 66.4 to 130.7 ng.h/mL, prolonged T_max from 0.5 to 2 h, and extended mean residence time indicating prolonged absorption and improved systemic availability. Conclusions: The optimized flibanserin-loaded cubosomal hydrogel successfully addresses key limitations of oral flibanserin therapy by enhancing transdermal permeation, sustaining plasma exposure, and avoiding first-pass hepatic metabolism. This nanostructured hydrogel represents a promising noninvasive platform for systemic flibanserin delivery and may provide a clinically relevant strategy to improve pharmacotherapy of hypoactive sexual desire disorder.</p></div>","PeriodicalId":577,"journal":{"name":"Future Journal of Pharmaceutical Sciences","volume":"12 1","pages":""},"PeriodicalIF":4.5,"publicationDate":"2026-08-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://link.springer.com/content/pdf/10.1186/s43094-026-01018-2.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148838129","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Novel RP-HPLC–PDA method for comprehensive stability indicating and impurity profiling for concurrent estimation of abiraterone and Niraparib in bulk and tablet formulation","authors":"Anusha Gandi,&nbsp;Krishnamanjari Pawar Amgoth","doi":"10.1186/s43094-026-01015-5","DOIUrl":"10.1186/s43094-026-01015-5","url":null,"abstract":"<div><h3>Background</h3><p>Abiraterone and Niraparib are widely used in cancer treatment particularly for managing prostate and ovarian cancers marketed with brand name Akeega. This study focuses on developing and validating an innovative, precise and stability-indicating RP-HPLC method designed to simultaneously quantify Abiraterone, Niraparib and their respective impurities in bulk and dosage form while also distinguishing degradation products formed under stress conditions. Chromatographic separation was achieved via isocratic elution using a Symmetry Shield RP-18 column (250 × 4.6 mm, 5 µm) with a mobile phase consisting of acetonitrile and buffer in a 40:60 v/v ratio. The flow rate was set at 1 mL/min at room temperature with a sample injection volume of 10 µL and detection was performed at 239 nm over a runtime of 24 min. The method was validated following ICH Q2 (R1) guidelines.</p><h3>Results</h3><p>Under optimized conditions, the retention times were noted as follows: Impurity A at 3.186 min, Impurity B at 4.771 min, Abiraterone at 6.409 min, Impurity C at 8.147 min, Impurity D at 10.132 min, Niraparib at 11.739 min, Impurity 1 at 13.456 min, Impurity 2 at 15.166 min, Impurity 3 at 16.976 min, and Impurity 4 at 18.396 min. Strong linearity was observed within the concentration ranges of 125–750 µg/mL for Abiraterone and 2.5–15 µg/mL for its impurities (A, B, C, D), as well as 25–150 µg/mL for Niraparib and 2.5–15 µg/mL for its impurities (1, 2, 3, 4). The percentage recovery of both drugs ranged from 99.8 to 100.6% across three concentration levels. The percentage RSD for both precision and robustness was within acceptable limits, while forced degradation studies demonstrated the method’s stability-indicating capacity by clearly differentiating between the active analyte peaks and degradation products.</p><h3>Conclusion</h3><p>By enabling simultaneous detection and quantification in a single run, this method effectively reduces analysis time and improves efficiency, supporting pharmaceutical quality control processes and ensuring compliance with regulatory standards.</p><h3>Graphical abstract</h3>\u0000<div><figure><div><div><picture><source><img></source></picture></div></div></figure></div></div>","PeriodicalId":577,"journal":{"name":"Future Journal of Pharmaceutical Sciences","volume":"12 1","pages":""},"PeriodicalIF":4.5,"publicationDate":"2026-08-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://link.springer.com/content/pdf/10.1186/s43094-026-01015-5.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148837357","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pharmacological inhibition of BUB1 suppresses UCEC progression by modulating the PI3K-AKT pathway and reversing anoikis resistance and immune evasion: a multi-omics and experimental study","authors":"Wajahat Ali,&nbsp;Mohd Abdullah Al Mamun,&nbsp;Yicheng He,&nbsp;Niaz Muhammad,&nbsp;Saleem Ahmed,&nbsp;Muhammad Umar,&nbsp; Kulsoom","doi":"10.1186/s43094-026-01017-3","DOIUrl":"10.1186/s43094-026-01017-3","url":null,"abstract":"<div><h3>Background</h3><p>Uterine corpus endometrial carcinoma (UCEC) is a prevalent gynecological malignancy with poor prognosis and limited therapeutic strategies. The mitotic checkpoint kinase BUB1 has emerged as a potential regulator of tumor progression, but its clinical and functional roles in UCEC remain unclear.</p><h3>Methods</h3><p>Transcriptomic datasets from TCGA and GEO were analyzed to evaluate BUB1 expression, survival impact, pathway enrichment, methylation, and immune infiltration. Protein–protein interactions and drug sensitivity analyses were performed using bioinformatics pipelines. Functional validation was conducted in HEC-1-B cells treated with the BUB1 inhibitor 2OH-BNPP1 using MTT, wound healing, and qPCR assays.</p><h3>Results</h3><p>BUB1 was significantly upregulated in UCEC tumors compared with normal endometrium, associated with advanced disease stage and reduced overall survival, confirming its role as an unfavorable prognostic biomarker. Enrichment analyses linked BUB1 to cell cycle regulation, PI3K-AKT signaling, and anoikis resistance. BUB1 expression positively correlated with infiltration of macrophages, neutrophils, and CD4⁺ T cells. Pharmacological inhibition with 2OH-BNPP1 reduced cell viability, impaired migration, and suppressed BUB1 expression in a dose-dependent manner, supporting its oncogenic role in endometrial carcinoma.</p><h3>Conclusion</h3><p>This study identifies BUB1 as a clinically relevant prognostic biomarker and therapeutic target in UCEC. Targeting BUB1 interrupts tumor-promoting processes including proliferation, survival, and migration, underscoring its translational potential for future therapeutic development.</p><h3>Graphical abstract</h3>\u0000<div><figure><div><div><picture><source><img></source></picture></div></div></figure></div></div>","PeriodicalId":577,"journal":{"name":"Future Journal of Pharmaceutical Sciences","volume":"12 1","pages":""},"PeriodicalIF":4.5,"publicationDate":"2026-08-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://link.springer.com/content/pdf/10.1186/s43094-026-01017-3.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148837356","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A randomized controlled trial evaluating the impact of curcumin versus pentoxifylline on patients with chronic kidney disease","authors":"Nada M. Kamel,&nbsp;Ahmed Elkoraie,&nbsp;Tarek M. Mostafa,&nbsp;Fedaa A. Kotkata","doi":"10.1186/s43094-026-01012-8","DOIUrl":"10.1186/s43094-026-01012-8","url":null,"abstract":"<div><h3>Background</h3><p>Chronic kidney disease (CKD) is a long-term, progressive disorder marked by a steady decline in renal function. It is frequently associated with complications such as anemia, bone and mineral imbalances, oxidative stress, and systemic inflammation. The buildup of uremic toxins, particularly p-cresyl sulfate (pCS), increases cardiovascular risk and mortality. Early diagnosis and timely treatment are essential to slow disease progression and enhance quality of life. This study investigates the nephroprotective roles of curcumin (–) and pentoxifylline (PTX) as adjunctive therapies alongside standard CKD management. Ninety-four CKD patients were randomized into three groups: control (standard care), – (500 mg twice daily), and PTX (400 mg twice daily) for 6 months. Renal function, electrolytes, and quality of life (KDQOL-SF™ v1.3) were assessed at baseline, 1, 3, and 6 months, while biomarkers (pCS, MDA, and Hs-CRP) were measured at baseline and after 6 months.</p><h3>Results</h3><p>After 6 months, – significantly reduced pCS (5.79 ± 3.74 to 5.02 ± 3.41 μg/mL, p = 0.011) and MDA levels (11.26 ± 7.37 to 10.43 ± 8.84 nmol/mL, p = 0.016), while the PTX group showed significant improvement in Hs-CRP levels (7.13 ± 3.53 to 5.52 ± 3.43 mg/L, p = 0.019) and albuminuria (p = 0.034 of ACR). Both treatments favorably affected creatinine, urea, and eGFR compared with control. After 6 months, serum creatinine showed improvement in both intervention groups, decreasing (3.58 ± 2.21 to 3.12 ± 2.18 mg/dL) in the – group and (2.75 ± 1.48 to 2.34 ± 1.17 mg/dL) in the PTX group (both p &lt; 0.001), BUN significantly decreased (41.03 ± 18.38 to 29.96 ± 13.46 mg/dL) and (35.29 ± 12.94 to 28.50 ± 14.59 mg/dL), respectively, compared with worsening values in the control group (both p &lt; 0.001) and eGFR increased (23.77 ± 13.35 to 28.50 ± 15.93 mL/min/1.73m²) and (30.29 ± 14.07 to 35.57 ± 15.40 mL/min/1.73m²), respectively (both p &lt; 0.001). Only mild gastrointestinal side effects were reported across all study groups, with no statistically significant differences between groups and no serious adverse events observed.</p><h3>Conclusions</h3><p>– and PTX treatment may provide adjunctive benefits in CKD by improving selected secondary outcomes related to oxidative stress, inflammation, and renal function.</p><h3>Clinical trial registration</h3><p>This study was retrospectively registered on ClinicalTrials.gov on June 12, 2024 (Identifier: <u>NCT06458465</u>) on https://clinicaltrials.gov/study/NCT06458465.</p></div>","PeriodicalId":577,"journal":{"name":"Future Journal of Pharmaceutical Sciences","volume":"12 1","pages":""},"PeriodicalIF":4.5,"publicationDate":"2026-08-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://link.springer.com/content/pdf/10.1186/s43094-026-01012-8.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148783000","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluation of relative safety and therapeutic efficacy of antihyperlipidemic drug regimens used alone or in combination in cardiovascular disease: randomized controlled study","authors":"Nourhan K. Elsaeed,&nbsp;Refaat H. Abdelmoety,&nbsp;Ehab Elyamani,&nbsp;Lamiaa mohamed Mahmoud,&nbsp;Mahmoud Zidan,&nbsp;Lamiaa Mohammed Matter,&nbsp;Mohamed S. Imam,&nbsp;Fahad Mofareh Alosaimi,&nbsp;Faisal Sultan Alosaimi,&nbsp;Abdullah Abdulrahman Almehery,&nbsp;Aryam Abdullah Asiri,&nbsp;Refan A Maadi,&nbsp;Hoda Rabea,&nbsp;Mona A. Abdelrahman","doi":"10.1186/s43094-026-01013-7","DOIUrl":"10.1186/s43094-026-01013-7","url":null,"abstract":"<div><h3>Background</h3><p>Statin monotherapy is a cornerstone of lipid-lowering therapy for reducing low-density lipoprotein cholesterol (LDL-C) and cardiovascular risk in patients with dyslipidemia. However, many patients at moderate-to-high cardiovascular risk fail to achieve recommended LDL-C targets with statin therapy alone, prompting interest in combination lipid-lowering strategies. Ezetimibe inhibits intestinal cholesterol absorption through Niemann–Pick C1-like 1 (NPC1L1) protein inhibition and may enhance LDL-C reduction while allowing lower statin doses, potentially improving tolerability.</p><h3>Objective</h3><p>To compare the efficacy and short-term safety of moderate-intensity rosuvastatin (10 mg) combined with ezetimibe (10 mg) versus high-intensity rosuvastatin (20 mg) monotherapy in patients with dyslipidemia.</p><h3>Methods</h3><p>This prospective randomized controlled study included 60 patients who completed 24 weeks of follow-up after random allocation to either rosuvastatin/ezetimibe (10/10 mg) combination therapy or rosuvastatin 20 mg monotherapy. Lipid profile, liver enzymes (AST and ALT), and creatine kinase (CK) were measured at baseline and at week 24. Continuous variables were analyzed using repeated-measures general linear modeling and mixed-model ANOVA after assessment of data normality. Safety evaluation included biochemical monitoring and clinical assessment for adverse events.</p><h3>Results</h3><p>Both treatment groups demonstrated significant reductions in total cholesterol and LDL-C from baseline (both <i>p</i> &lt; 0.001). Post-treatment LDL-C was significantly lower in the combination group than in the monotherapy group (71.83 ± 12.14 vs. 86.30 ± 23.87 mg/dL; <i>p</i> = 0.004), whereas reductions in total cholesterol, triglycerides, and HDL-C changes were comparable between groups. Absolute post-treatment AST and ALT values did not differ significantly between treatment groups. However, percentage increases from baseline were significantly smaller in the combination group for AST (15.38% vs. 35.71%; <i>p</i> = 0.015) and ALT (14.28% vs. 21.11%; <i>p</i> = 0.018). Importantly, mean liver enzyme values in both groups remained well below clinically significant hepatotoxicity thresholds throughout follow-up. No major adverse cardiovascular events occurred during the 24-week study period.</p><h3>Conclusions</h3><p>Moderate-intensity rosuvastatin combined with ezetimibe achieved lipid-lowering efficacy comparable to high-intensity rosuvastatin while producing lower relative increases in liver enzymes over 24 weeks. These findings suggest that combination therapy represents a reasonable therapeutic alternative for selected patients requiring intensive LDL-C reduction; however, larger multicenter studies with longer follow-up are needed to establish comparative cardiovascular outcomes and overall safety.</p><h3>Clinical trials</h3><p>https://clinicaltrials.gov/study/NCT07313124.</p></div>","PeriodicalId":577,"journal":{"name":"Future Journal of Pharmaceutical Sciences","volume":"12 1","pages":""},"PeriodicalIF":4.5,"publicationDate":"2026-08-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://link.springer.com/content/pdf/10.1186/s43094-026-01013-7.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148751800","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Analytical method development, validation for the estimation of brivaracetam in bulk drug substance by RP-HPLC and identification of its major degradation product: a quality by design approach","authors":"Sandip Kumar Dey,&nbsp;Koustav Dutta,&nbsp;Sumanta Mondal,&nbsp;Sagar Suman Panda,&nbsp;Prasenjit Mondal","doi":"10.1186/s43094-026-01010-w","DOIUrl":"10.1186/s43094-026-01010-w","url":null,"abstract":"<div><h3>Background</h3><p>The research involved a systematic and proactive approach, integrating quality considerations throughout the product lifecycle, from initial conception to final production. A design space was established by thoroughly examining these relationships, ensuring the product consistently meets desired quality standards.</p><h3>Objective</h3><p>This study employed an approach of Quality by Design (AQbD) strategy for developing and validating stability-indicating method for the estimation of brivaracetam in bulk drug substance via RP-HPLC, including characterizing its major degradation products.</p><h3>Methods</h3><p>The analytical separation was performed using a Waters Alliance HPLC system, equipped with an X-Terra RP18 column (250 × 4.6 mm, 5 µm), and a gradient elution technique with mobile phases A (0.1% w/v perchloric acid in water) and B (water: acetonitrile, 10:90, v/v) at a flow rate of 1.2 mL/min, resulting in a retention time of about 16.8 min.</p><h3>Results</h3><p>The major degradation product was identified as (S)-2-((R)-2-oxo-4-propylpyrrolidin-1-yl)butanoic acid, with a retention time of 23.6 min, significantly different from brivaracetam. The percentage of degradation in acid conditions was found to be 10%. The method demonstrated high accuracy, with recovery rates between 99.7% and 100.4%. The %RSD value for the method and intermediate precision was 0.2% and 0.3%, respectively.</p><h3>Conclusions</h3><p>The Approach Quality by Design (AQbD) methodology enabled a comprehensive understanding of the factors influencing chromatographic separation, enhancing assurance in the established HPLC method’s capacity to fulfill its intended objectives.</p></div>","PeriodicalId":577,"journal":{"name":"Future Journal of Pharmaceutical Sciences","volume":"12 1","pages":""},"PeriodicalIF":4.5,"publicationDate":"2026-08-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://link.springer.com/content/pdf/10.1186/s43094-026-01010-w.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148751475","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pyrazolo[3,4-b]pyridine: a privileged scaffold for the synthesis of anti-Alzheimer’s agents","authors":"Omnia M. Waly,&nbsp;Selwan M. El-Sayed,&nbsp;Mariam A. Ghaly,&nbsp;Hussein I. El-Subbagh","doi":"10.1186/s43094-026-01006-6","DOIUrl":"10.1186/s43094-026-01006-6","url":null,"abstract":"<div><p>Alzheimer’s disease (AD) is known to be the most prevalent neurodegenerative disorder that results in dementia and causes a variety of cognitive symptoms. There are many important aspects of AD that should be considered, even though the exact sequence of events is unclear. These aspects include the cholinergic theory, the amyloid beta (Aβ) hypothesis, and the hyperphosphorylated <i>tau</i> protein that forms neurofibrillary tangles (NFTs). Furthermore, pyrazolo[3,4-<i>b</i>]pyridine-based derivatives exhibited therapeutic potential on AD management. The causes of AD and all the reported possible options for pyrazolo[3,4-<i>b</i>]pyridine derivatives for treating AD, together with their synthetic pathways, are the main highlights of this article, where such derivatives are reviewed from the reported data gathered without date restriction. Finally, a collective SAR study to explain the requirements to design a MTDL based on pyrazolo[3,4-<i>b</i>]pyridine scaffold is also presented.</p></div>","PeriodicalId":577,"journal":{"name":"Future Journal of Pharmaceutical Sciences","volume":"12 1","pages":""},"PeriodicalIF":4.5,"publicationDate":"2026-08-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://link.springer.com/content/pdf/10.1186/s43094-026-01006-6.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148751206","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Bioinformatic design of optimized therapeutic peptides for targeted breast cancer therapy","authors":"Elijah Kolawole Oladipo,&nbsp;Omolara Omoboye Adegboye,&nbsp;Stephen Feranmi Adeyemo,&nbsp;Modinat Wuraola Akinboade,&nbsp;Bamidele Abiodun Iwalokun,&nbsp;Olumide Faith Ajani,&nbsp;Olumuyiwa Elijah Ariyo,&nbsp;Helen Onyeaka","doi":"10.1186/s43094-026-01009-3","DOIUrl":"10.1186/s43094-026-01009-3","url":null,"abstract":"<div><p>Breast cancer remains a leading cause of mortality among women globally, underscoring the urgent need for novel therapies that combine high efficacy with minimal adverse effects. This study examines the bioinformatic design of animal-derived therapeutic peptides targeting two key breast cancer biomarkers: matrix metalloproteinase 1 (MMP1) and epidermal growth factor receptor (EGFR). Approximately 1,500 antimicrobial peptides were retrieved from the antimicrobial peptide database 3 (APD3). They were screened for hemolytic properties using the Hemolytik database. This screening resulted in 255 non-hemolytic candidates, which were further screened through VaxiJen 2.0 and ToxinPred2 for antigenicity and allergenicity. Moreover, physicochemical properties were analyzed using the Expasy ProtParam server. We applied thresholds of molecular weight (1.7–3.1 kDa), instability index (≤ 28), and net charge (+ 2 to + 7). Five peptides met all criteria and were screened for anticancer potential using AntiCP 2.0 and ACPred, identifying three overlapping anticancer peptides (ACPs), including Metalnikowin IIA (AP00363) from <i>Palomena prasina</i>, Guentherin (AP00584) from <i>Hylarana guentheri</i>, and P-10 (AP02393) from <i>Ciona intestinalis</i>. Furthermore, peptide structures were modeled using Colab AlphaFold2. Tertiary structures of target proteins were obtained from UniProt, and Buserelin (FDA-approved ACP) was obtained from the DCTPep database. All peptides were docked against MMP1 and EGFR using HDock and ClusPro. AP00363 showed the highest docking affinity with MMP1 and EGFR, scoring −235.61 and −271.70, respectively. Molecular dynamics simulations supported the stability and interaction potential of these peptides. Overall, this study presents promising bioinformatically designed, animal-derived ACPs for targeted breast cancer therapy. Further in vitro and in vivo validation is necessary to assess clinical relevance.</p></div>","PeriodicalId":577,"journal":{"name":"Future Journal of Pharmaceutical Sciences","volume":"12 1","pages":""},"PeriodicalIF":4.5,"publicationDate":"2026-08-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://link.springer.com/content/pdf/10.1186/s43094-026-01009-3.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148750763","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Recent applications of liquid chromatography tandem mass spectrometry at various stages of drug development","authors":"Sunita Sunil Gagare,&nbsp;Vaishnavi Bhau Thorat,&nbsp;Ashish Suresh Jain","doi":"10.1186/s43094-026-01011-9","DOIUrl":"10.1186/s43094-026-01011-9","url":null,"abstract":"<div><h3>Background</h3><p>Liquid chromatography–tandem mass spectrometry is a combination of liquid chromatography and mass spectrometry. In this process, high-performance liquid chromatography separates analytes, ionizes them, and then analyzes them using mass filters that are based on mass-to-charge ratio. The strength of the signal shows the concentration. It surpasses traditional high-performance liquid chromatography and immunoassays in sensitivity, specificity, and multi-analyte capabilities, offering better throughput than gas chromatography–mass spectrometry while accommodating higher molecular weight or highly polar molecules. Liquid chromatography–tandem mass spectrometry is widely used in therapeutic drug monitoring, endocrinology, and toxicology.</p><h3>Main text</h3><p>This article outlines the advantages and pharmaceutical applications of LC–MS/MS in quantifying various drugs, metabolites, and genotoxic impurities. It is also used in therapeutic drug monitoring and proteomics. This technique allows for precise quantification of compounds, including antidepressants, antipsychotics, benzodiazepines, antifungals, and antihypertensives across diverse biological matrices. Therapeutic drug monitoring benefits from LC–MS/MS by accurately measuring drug levels to optimize dosage for drugs with narrow therapeutic ranges, like immunosuppressant and anticancer drugs. It also quantifies genotoxic impurities, such as sulfonate esters and nitrosamine impurities, in drug substances. LC–MS/MS is also used in stability-indicating methods for various drugs and for the quantification of drugs in dosage forms. Excellent sensitivity and specificity within protein analysis in proteomics are achievable with LC–MS/MS. Thousands of proteins can be precisely measured through methods like parallel reaction monitoring and selected reaction monitoring.</p><h3>Conclusion</h3><p>LC–MS/MS is a fast and accurate way to measure different drugs, metabolites, and genotoxic impurities in pharmaceutical analysis. It is also used in stability-indicating methods and for the quantification of drugs in dosage forms. Compared to high-performance liquid chromatography with ultraviolet detection, radioimmunoassay, enzyme-linked immunosorbent assay, and gas chromatography–mass spectrometry, liquid chromatography–tandem mass spectrometry is a powerful analytical method that offers quick, precise analysis and improved selectivity and sensitivity.</p></div>","PeriodicalId":577,"journal":{"name":"Future Journal of Pharmaceutical Sciences","volume":"12 1","pages":""},"PeriodicalIF":4.5,"publicationDate":"2026-07-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://link.springer.com/content/pdf/10.1186/s43094-026-01011-9.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148614821","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Characterization of biofilm development and antimicrobial susceptibility profiles in Acinetobacter baumannii clinical isolates","authors":"Eman Abdelbaset,&nbsp;Marwa A. Shahin,&nbsp;Amal E. Ali,&nbsp;Reham Samir,&nbsp;Marwa M. Raafat","doi":"10.1186/s43094-026-00978-9","DOIUrl":"10.1186/s43094-026-00978-9","url":null,"abstract":"<div><h3>Background</h3><p><i>Acinetobacter baumannii</i> is recognized as a major cause of nosocomial infections due to its strong biofilm formation tendency and acquired resistance to multiple antibiotics. These are factors that complicate treatment and increase patient risk. In this study, we investigated the correlation between biofilm-forming capacity, antimicrobial susceptibility profiles, and the prevalence of three essential genetic determinants: omp<i>A</i>, bap, and blaPER-1. The identification of 72 clinical isolates was achieved via the biochemical testing and blaOXA-51 gene detection. Subsequently, susceptibility to antimicrobials was measured by using either broth microdilution or disk diffusion. Biofilm development was assessed through the crystal violet staining technique, while the presence and the expression levels of target genes were analyzed using PCR and qPCR.</p><h3>Results</h3><p>High resistance rates (69.4–98.6%) were observed against most antibiotics with tigecycline showing the lowest resistance (12.5%). Most isolates (86.1%) were capable of forming biofilms to varying degrees. In addition, omp<i>A</i> and bap were widely distributed among all isolates, while <i>blaPER-1</i> was detected only in biofilm-forming isolates. Expression of all three genes increased with the strength of biofilm formation, and it was positively correlated with antibiotic resistance, highlighting their potential role in development of both biofilm and multidrug resistance.</p><h3>Conclusion</h3><p><i>A. baumannii</i> demonstrated a robust capacity for biofilm production and exhibited extensive multidrug resistance against different antibiotics, with critical role of omp<i>A</i>, bap, and blaPER-1genes. blaPER-1 was detected only in biofilm-forming isolates in this study, suggesting that it may serve as a potential marker associated with biofilm-producing strains. Gene expression analysis revealed that the levels of these genes consistently increased with the degree of biofilm formation. These findings provide valuable insight into the association between <i>A. baumannii</i> biofilm, antibiotic resistance, and gene regulation and also underscore the necessity for further studies to explore their potential as a therapeutic intervention.</p></div>","PeriodicalId":577,"journal":{"name":"Future Journal of Pharmaceutical Sciences","volume":"12 1","pages":""},"PeriodicalIF":4.5,"publicationDate":"2026-07-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://link.springer.com/content/pdf/10.1186/s43094-026-00978-9.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148613186","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}